Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04176354 · ClinicalTrials.gov registry record
Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 813
- Enrollment target
NCT04176354 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 813 participants.
The verdict
NCT04176354 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 813 participants
- Enrollment target
Study Summary
A retrospective observational analysis of de-identified Flatiron Health Analytic Database to describe patient characteristics, treatment patterns and effectiveness of Palbociclib + AI as first-line therapy in HR+/HER2- metastatic breast cancer (MBC) in the US clinical practices.
Interventions
- DRUG Letrozole
- DRUG Palbociclib + an aromatase inhibitor
- DRUG Palbociclib + Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 813 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2019-09-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04176354
The ClinicalTrials.gov registry entry for NCT04176354 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 813 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Letrozole is the first listed.
NCT04176354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04176354 about?
NCT04176354 is a clinical study titled "Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy". A retrospective observational analysis of de-identified Flatiron Health Analytic Database to describe patient characteristics, treatment patterns and effectiveness of Palbociclib + AI as first-line therapy in HR+/HER2- metastatic breast cancer (MBC) in the US clinical practices.
What is the current status of trial NCT04176354?
This trial is currently completed. The enrollment target is 813 participants. The study started on 2019-01-25. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT04176354?
The interventions under investigation include: Letrozole (DRUG), Palbociclib + an aromatase inhibitor (DRUG), Palbociclib + Letrozole (DRUG).
Who is sponsoring clinical trial NCT04176354?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.